Scleroderma renal crisis

Journal of Rheumatology

Volumn 41, Issue 6, 2014, Pages 1040-1048

  Mouthon, Luc ^a,b   Bussone, Guillaume ^a,b   Berezné, Alice ^a,b   Noël, Laure Hélène ^b,c   Guillevin, Loïc ^a,b  

^a UNIVERSITÉ PARIS DESCARTES   (France)

^b INSTITUT COCHIN   (France)

^c HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

Acute renal failure; Angiotensin converting enzyme inhibitors; Endothelin 1; Hypertension; Scleroderma renal crisis; Systemic sclerosis

Indexed keywords

ANTINUCLEAR ANTIBODY; CORTICOSTEROID; CREATINE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; MINOXIDIL; PRAZOSIN; PROSTACYCLIN; ANTIHYPERTENSIVE AGENT;

ACUTE KIDNEY FAILURE; BLOOD PRESSURE REGULATION; CLINICAL TRIAL (TOPIC); CONGESTIVE HEART FAILURE; DIFFERENTIAL DIAGNOSIS; EARLY DIAGNOSIS; HEART ARRHYTHMIA; HUMAN; HYPERTENSION ENCEPHALOPATHY; INCIDENCE; KIDNEY TRANSPLANTATION; MALIGNANT HYPERTENSION; PATHOPHYSIOLOGY; PREDICTOR VARIABLE; PREGNANCY; PREVALENCE; PRIORITY JOURNAL; PROGNOSIS; RENAL REPLACEMENT THERAPY; REVIEW; RISK FACTOR; SCLERODERMA RENAL CRISIS; SURVIVAL; ACUTE KIDNEY INJURY; COMPLICATION; SCLERODERMA, SYSTEMIC;

ACUTE KIDNEY INJURY; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANTIHYPERTENSIVE AGENTS; HUMANS; SCLERODERMA, SYSTEMIC;

EID: 84901709219     PISSN: 0315162X     EISSN: 14992752     Source Type: Journal    
DOI: 10.3899/jrheum.131210     Document Type: Review

References (72)

1. Moore H, Sheehan H. The kidney of scleroderma. Lancet 1952;1:68-70.
2. Steen VD. Scleroderma renal crisis. Rheum Dis Clin North Am 2003;29:315-33. (Pubitemid 36765123)
3. Traub YM, Shapiro AP, Rodnan GP, Medsger TA, McDonald RH, Steen VD, et al. Hypertension and renal failure (scleroderma renal crisis) in progressive systemic sclerosis. Review of a 25-year experience with 68 cases. Medicine 1983;62:335-52. (Pubitemid 14201907)
4. Steen VD, Costantino JP, Shapiro AP, Medsger TA. Outcome of renal crisis in systemic sclerosis: relation to availability of angiotensin converting enzyme (ACE) inhibitors. Ann Intern Med 1990;113:352-7. (Pubitemid 20262820)
5. DeMarco PJ, Weisman MH, Seibold JR, Furst DE, Wong WK, Hurwitz EL, et al. Predictors and outcomes of scleroderma renal crisis: the high-dose versus low-dose D-penicillamine in early diffuse systemic sclerosis trial. Arthritis Rheum 2002;46:2983-9. (Pubitemid 35315892)
6. Walker JG, Ahern MJ, Smith MD, Coleman M, Pile K, Rischmueller M, et al. Scleroderma renal crisis: poor outcome despite aggressive antihypertensive treatment. Intern Med J 2003;33:216-20. (Pubitemid 36718377)
7. Teixeira L, Mouthon L, Mahr A, Berezne A, Agard C, Mehrenberger M, et al. Mortality and risk factors of scleroderma renal crisis: a French retrospective study of 50 patients. Ann Rheum Dis 2008;67:110-6.
8. Penn H, Howie AJ, Kingdon EJ, Bunn CC, Stratton RJ, Black CM, et al. Scleroderma renal crisis: patient characteristics and long-term outcomes. QJM 2007;100:485-94. (Pubitemid 47241915)
9. Helfrich DJ, Banner B, Steen VD, Medsger TA. Normotensive renal failure in systemic sclerosis. Arthritis Rheum 1989;32:1128-34. (Pubitemid 19237867)
10. Mouthon L, Berezne A, Bussone G, Noël LH, Villiger PM, Guillevin L. Scleroderma renal crisis: a rare but severe complication of systemic sclerosis. Clin Rev Allergy Immunol 2011;40:84-91.
11. Denton CP, Lapadula G, Mouthon L, Muller-Ladner U. Renal complications and scleroderma renal crisis. Rheumatology 2009;48 Suppl 3:iii32-5.
12. Charles C, Clements P, Furst DE. Systemic sclerosis: hypothesis-driven treatment strategies. Lancet 2006;367:1683-91. (Pubitemid 43728250)
13. Cannon PJ, Hassar M, Case DB, Casarella WJ, Sommers SC, LeRoy EC. The relationship of hypertension and renal failure in scleroderma (progressive systemic sclerosis) to structural and functional abnormalities of the renal cortical circulation. Medicine 1974;53:1-46.
14. Rivolta R, Mascagni B, Berruti V, Quarto Di Palo F, Elli A, Scorza R, et al. Renal vascular damage in systemic sclerosis patients without clinical evidence of nephropathy. Arthritis Rheum 1996;39:1030-4. (Pubitemid 26182073)
15. Woolfson RG, Cairns HS, Williams DJ, Hilson AJ, Neild GH. Renal scintigraphy in acute scleroderma: report of three cases. J Nucl Med 1993;34:1163-5. (Pubitemid 23191335)
16. Shapiro L, Prince R, Buckingham R. D-penicillamine treatment of progressive systemic sclerosis (scleroderma). A comparison of clinical and in vitro effects. J Rheumatol 1983;10:316.
17. Clements PJ, Lachenbruch PA, Furst DE, Maxwell M, Danovitch G, Paulus HE. Abnormalities of renal physiology in systemic sclerosis. A prospective study with 10-year followup. Arthritis Rheum 1994;37:67-74. (Pubitemid 24027695)
18. Steen VD, Medsger TA, Osial TA, Ziegler GL, Shapiro AP, Rodnan GP. Factors predicting development of renal involvement in progressive systemic sclerosis. Am J Med 1984;76:779-86. (Pubitemid 14142675)
19. Steen VD, Conte C, Day N, Ramsey-Goldman R, Medsger TA. Pregnancy in women with systemic sclerosis. Arthritis Rheum 1989;32:151-7. (Pubitemid 19056402)
20. Steen VD. Pregnancy in women with systemic sclerosis. Obstet Gynecol 1999;94:15-20. (Pubitemid 29284419)
21. Lam M, Ballou SP. Reversible scleroderma renal crisis after cocaine use. N Engl J Med 1992;326:1435.
22. Denton CP, Sweny P, Abdulla A, Black CM. Acute renal failure occurring in scleroderma treated with cyclosporin A: a report of three cases. Br J Rheumatol 1994;33:90-2. (Pubitemid 24042045)
23. Steen VD, Medsger TA. Case-control study of corticosteroids and other drugs that either precipitate or protect from the development of scleroderma renal crisis. Arthritis Rheum 1998;41:1613-9. (Pubitemid 28459919)
24. Vancheeswaran R, Magoulas T, Efrat G, Wheeler-Jones C, Olsen I, Penny R, et al. Circulating endothelin-1 levels in systemic sclerosis subsets - a marker of fibrosis or vascular dysfunction? J Rheumatol 1994;21:1838-44. (Pubitemid 24312644)
25. Kobayashi H, Nishimaki T, Kaise S, Suzuki T, Watanabe K, Kasukawa R. Immunohistological study endothelin-1 and endothelin-A and B receptors in two patients with scleroderma renal crisis. Clin Rheumatol 1999;18:425-7. (Pubitemid 29479775)
26. Penn H, Quillinan N, Khan K, Chakravarty K, Ong VH, Burns A, et al. Targeting the endothelin axis in scleroderma renal crisis: rationale and feasibility. QJM 2013;106:839-48.
27. Fisher E, Rodnan G. Pathologic observations concerning the kidney in progressive systemic sclerosis. AMA Arch Pathol 1958;65:29-39.
28. Batal I, Domsic RT, Medsger TA, Bastacky S. Scleroderma renal crisis: a pathology perspective. Int J Rheumatol 2010;2010:543704.
29. Batal I, Domsic RT, Shafer A, Medsger TA Jr., Kiss LP, Randhawa P, et al. Renal biopsy findings predicting outcome in scleroderma renal crisis. Hum Pathol 2009;40:332-40.
30. Trostle DC, Bedetti CD, Steen VD, Al-Sabbagh MR, Zee B, Medsger TA. Renal vascular histology and morphometry in systemic sclerosis. A case-control autopsy study. Arthritis Rheum 1988;31:393-400. (Pubitemid 18091662)
31. Kirschstein M, Helmchen U, Jensen R, Kuster RM, Lehmann H. Kidney involvement in a 17-year-old boy with eosinophilic fasciitis. Clin Nephrol 1999;52:183-7. (Pubitemid 29419474)
32. Lapenas D, Rodnan GP, Cavallo T. Immunopathology of the renal vascular lesion of progressive systemic sclerosis (scleroderma). Am J Pathol 1978;91:243-58. (Pubitemid 8334884)
33. McGiven AR, De Boer WG, Barnett AJ. Renal immune deposits in scleroderma. Pathology 1971;3:145-50.
34. Ranque B, Mouthon L. Geoepidemiology of systemic sclerosis. Autoimmun Rev 2010;9:A311-8.
35. Mayes MD, Lacey JV Jr., Beebe-Dimmer J, Gillespie BW, Cooper B, Laing TJ, et al. Prevalence, incidence, survival, and disease characteristics of systemic sclerosis in a large US population. Arthritis Rheum 2003;48:2246-55. (Pubitemid 36959206)
36. Roberts-Thomson PJ, Walker JG. Scleroderma: it has been a long hard journey. Intern Med J 2006;36:519-23. (Pubitemid 43990904)
37. Tamaki T, Mori S, Takehara K. Epidemiological study of patients with systemic sclerosis in Tokyo. Arch Dermatol Res 1991;283:366-71.
38. Le Guern V, Mahr A, Mouthon L, Jeanneret D, Carzon M, Guillevin L. Prevalence of systemic sclerosis in a French multi-ethnic county. Rheumatology 2004;43:1129-37. (Pubitemid 39232818)
39. Magnant J, Diot E. [Systemic sclerosis: epidemiology and environmental factors]. In French. Presse Med 2006;35(12 Pt 2):1894-901.
40. Walker UA, Tyndall A, Czirjak L, Denton C, Farge-Bancel D, Kowal-Bielecka O, et al. Clinical risk assessment of organ manifestations in systemic sclerosis: a report from the EULAR Scleroderma Trials And Research group database. Ann Rheum Dis 2007;66:754-63.
41. Denton CP, Black CM. Scleroderma - clinical and pathological advances. Best Pract Res Clin Rheumatol 2004;18:271-90. (Pubitemid 38950054)
42. Clements PJ, Hurwitz EL, Wong WK, Seibold JR, Mayes M, White B, et al. Skin thickness score as a predictor and correlate of outcome in systemic sclerosis: high-dose versus low-dose penicillamine trial. Arthritis Rheum 2000;43:2445-54.
43. Bussone G, Noël LH, Mouthon L. [Renal involvement in patients with systemic sclerosis]. In French. Nephrol Ther 2011;7:192-9.
44. Kuwana M, Okano Y, Pandey JP, Silver RM, Fertig N, Medsger TA Jr. Enzyme-linked immunosorbent assay for detection of anti-RNA polymerase III antibody: analytical accuracy and clinical associations in systemic sclerosis. Arthritis Rheum 2005;52:2425-32. (Pubitemid 41117428)
45. Hesselstrand R, Scheja A, Shen GQ, Wiik A, Akesson A. The association of antinuclear antibodies with organ involvement and survival in systemic sclerosis. Rheumatology 2003;42:534-40. (Pubitemid 36432472)
46. Nikpour M, Hissaria P, Byron J, Sahhar J, Micallef M, Paspaliaris W, et al. Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort. Arthritis Res Ther 2011;13:R211.
47. Kang EH, Lee EB, Kim DJ, Im CH, Lee HJ, Song YW. Anti-RNA polymerase antibodies in Korean patients with systemic sclerosis and their association with clinical features. Clin Exp Rheumatol 2005;23:731-2. (Pubitemid 41300732)
48. Bardoni A, Rossi P, Salvini R, Bobbio-Pallavicini F, Caporali R, Montecucco C. Autoantibodies to RNA-polymerases in Italian patients with systemic sclerosis. Clin Exp Rheumatol 2003;21:301-6. (Pubitemid 36747824)
49. Emilie S, Goulvestre C, Bérezné A, Pagnoux C, Guillevin L, Mouthon L. Anti-RNA polymerase III antibodies are associated with scleroderma renal crisis in a French cohort. Scand J Rheumatol 2011;40:404-6.
50. Meyer O, De Chaisemartin L, Nicaise-Roland P, Cabane J, Tubach F, Dieude P, et al. Anti-RNA polymerase III antibody prevalence and associated clinical manifestations in a large series of French patients with systemic sclerosis: a cross-sectional study. J Rheumatol 2010;37:125-30.
51. Bunn CC, Denton CP, Shi-Wen X, Knight C, Black CM. Anti-RNA polymerases and other autoantibody specificities in systemic sclerosis. Br J Rheumatol 1998;37:15-20.
52. Steen VD. Autoantibodies in systemic sclerosis. Semin Arthritis Rheum 2005;35:35-42. (Pubitemid 41111469)
53. Codullo V, Cavazzana I, Bonino C, Alpini C, Cavagna L, Cozzi F, et al. Serologic profile and mortality rates of scleroderma renal crisis in Italy. J Rheumatol 2009;36:1464-9.
54. Vaughan JH, Shaw PX, Nguyen MD, Medsger TA Jr., Wright TM, Metcalf JS, et al. Evidence of activation of 2 herpes viruses, Epstein-Barr virus and cytomegalovirus, in systemic sclerosis and normal skins [letter]. J Rheumatol 2000;27:821-3. (Pubitemid 30151374)
55. Steen V. Predictors of end stage lung disease in systemic sclerosis. Ann Rheum Dis 2003;62:97-9. (Pubitemid 36135382)
56. Manadan AM, Harris C, Block JA. Thrombotic thrombocytopenic purpura in the setting of systemic sclerosis. Semin Arthritis Rheum 2005;34:683-8. (Pubitemid 40193367)
57. Molina JF, Anaya JM, Cabrera GE, Hoffman E, Espinoza LR. Systemic sclerosis sine scleroderma: an unusual presentation in scleroderma renal crisis. J Rheumatol 1995;22:557-60.
58. Gonzalez EA, Schmulbach E, Bastani B. Scleroderma renal crisis with minimal skin involvement and no serologic evidence of systemic sclerosis. Am J Kidney Dis 1994;23:317-9. (Pubitemid 24075329)
59. Anders HJ, Wiebecke B, Haedecke C, Sanden S, Combe C, Schlondorff D. MPO-ANCA-Positive crescentic glomerulonephritis: a distinct entity of scleroderma renal disease? Am J Kidney Dis 1999;33:e3.
60. Steen VD, Syzd A, Johnson JP, Greenberg A, Medsger TA Jr. Kidney disease other than renal crisis in patients with diffuse scleroderma. J Rheumatol 2005;32:649-55. (Pubitemid 40524696)
61. Quemeneur T, Mouthon L, Cacoub P, Meyer O, Michon-Pasturel U, Vanhille P, et al. Systemic vasculitis during the course of systemic sclerosis: report of 12 cases and review of the literature. Medicine 2013;92:1-9.
62. Okano Y, Steen VD, Medsger TA. Autoantibody reactive with RNA polymerase III in systemic sclerosis. Ann Intern Med 1993;119:1005-13. (Pubitemid 23334657)
63. Lopez-Ovejero JA, Saal SD, D'Angelo WA, Cheigh JS, Stenzel KH, Laragh JH. Reversal of vascular and renal crises of scleroderma by oral angiotensin-converting-enzyme blockade. N Engl J Med 1979;300:1417-9. (Pubitemid 9212124)
64. Caskey FJ, Thacker EJ, Johnston PA, Barnes JN. Failure of losartan to control blood pressure in scleroderma renal crisis. Lancet 1997;349:620. (Pubitemid 27101895)
65. Steen VD, Medsger TA. Long-term outcomes of scleroderma renal crisis. Ann Intern Med 2000;133:600-3.
66. Pham PT, Pham PC, Danovitch GM, Gritsch HA, Singer J, Wallace WD, et al. Predictors and risk factors for recurrent scleroderma renal crisis in the kidney allograft: case report and review of the literature. Am J Transplant 2005;5:2565-9.
67. Montanelli G, Beretta L, Santaniello A, Scorza R. Effect of dihydropyridine calcium channel blockers and glucocorticoids on the prevention and development of scleroderma renal crisis in an Italian case series. Clin Exp Rheumatol 2013;31 Suppl 76:135-9.
68. Steen VD, Medsger TA. Changes in causes of death in systemic sclerosis, 1972-2002. Ann Rheum Dis 2007;66:940-4. (Pubitemid 46999798)
69. Maddison P. Prevention of vascular damage in scleroderma with angiotensin-converting enzyme (ACE) inhibition. Rheumatology 2002;41:965-71.
70. Hudson M, Baron M, Tatibouet S, Furst DE, Khanna D; International Scleroderma Renal Crisis Study Investigators. Exposure to ACE inhibitors prior to the onset of scleroderma renal crisis - Results from the International Scleroderma Renal Crisis Survey. Semin Arthritis Rheum 2013 Oct 7 (E-pub ahead of print).
71. Teixeira L, Mahr A, Berezne A, Noel LH, Guillevin L, Mouthon L. Scleroderma renal crisis, still a life-threatening complication. Ann N Y Acad Sci 2007;1108:249-58. (Pubitemid 47528738)
72. Guillevin L, Berezne A, Seror R, Teixeira L, Pourrat J, Mahr A, et al. Scleroderma renal crisis: a retrospective multicentre study on 91 patients and 427 controls. Rheumatology 2012;51:460-7.